Risk factors for intrahepatic recurrence of hepatocellular carcinoma in cirrhotic patients treated by percutaneous ethanol injection
BACKGROUND Hepatocellular carcinoma (HCC) complicating cirrhosis has a high intrahepatic recurrence rate after treatment by surgical resection or percutaneous ethanol injection (PEI). In this study, certain clinical, biochemical, and pathologic parameters were evaluated as risk factors for intrahepa...
Gespeichert in:
| Veröffentlicht in: | Cancer 1997-04, Vol.79 (8), p.1501-1508 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1508 |
|---|---|
| container_issue | 8 |
| container_start_page | 1501 |
| container_title | Cancer |
| container_volume | 79 |
| creator | Pompili, Maurizio Rapaccini, Gian Ludovico de Luca, Francescantonio Caturelli, Eugenio Astone, Antonio Siena, Domenico Angelo Villani, Maria Rosaria Grattagliano, Anna Cedrone, Augusto Gasbarrini, Giovanni |
| description | BACKGROUND
Hepatocellular carcinoma (HCC) complicating cirrhosis has a high intrahepatic recurrence rate after treatment by surgical resection or percutaneous ethanol injection (PEI). In this study, certain clinical, biochemical, and pathologic parameters were evaluated as risk factors for intrahepatic tumor recurrence in liver segments different from that of the first neoplasm in a group of 57 cirrhotic patients with single HCC < 5 cm treated by PEI.
METHODS
After PEI treatment of HCC, the patients were followed for a mean period of 33 ± 16 months. The following pretreatment parameters were evaluated as predictors of tumor recurrence: age, gender, Child‐Pugh score, hepatitis B virus surface antigen, hepatitis C virus antibodies, alanine aminotransferase, aspartate aminotransferase, alpha‐fetoprotein (AFP) level before PEI, alcohol abuse, HCC size, HCC ultrasound pattern, HCC histologic grade, HCC capsule, and time from cirrhosis diagnosis. Furthermore, the posttreatment parameters of the AFP level 1 month after PEI and recurrence of HCC in the same liver segment were also evaluated.
RESULTS
The cumulative 4‐year intrahepatic recurrence rate of HCC was 62%. The log rank test indicated that, among pretreatment parameters, time from cirrhosis diagnosis >6 years (P = 0.05) and AFP level before PEI of >25 ng/mL (P = 0.00005) were significantly linked to tumor recurrence. Cox's proportional hazards model showed that only AFP level before PEI was independently associated with recurrence (P < 0.002). With regard to posttreatment parameters, an AFP level 1 month after PEI of >13 ng/mL was shown to be significantly related to tumor recurrence by the log rank test (P < 0.0001).
CONCLUSIONS
Cirrhotic patients with single HCC treated by PEI who have slightly increased serum levels of AFP before and/or after PEI treatment are at increased risk of intrahepatic tumor recurrence and should undergo a close follow‐up program. Cancer 1997; 79:1501‐8. © 1997 American Cancer Society.
Cirrhotic patients with a single hepatocellular carcinoma 25 ng/mL and 13 ng/mL prior to and 1 month after the treatment, respectively. |
| doi_str_mv | 10.1002/(SICI)1097-0142(19970415)79:8<1501::AID-CNCR9>3.0.CO;2-D |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78924850</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78924850</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4649-fe551e11521c571dc6a48b274cfd46be03ef2459090fb8fd1232b890b18422863</originalsourceid><addsrcrecordid>eNqFkU-P0zAQxSMEWroLHwHJB4R2Dyljx27sLkKsUv5UWlFpAWk5jRzXVrOkcbETrXrng5NsSi8gcbI8897ozfyS5B2FKQVgr8-_LIvlBQWVp0A5O6dK5cCpuMjVXL6hAuh8frVcpMXn4ka9zaYwLVaXLF08SiZH0-NkAgAyFTy7fZqcxnjXf3MmspPkRFEqIYNJ8uumij-I06b1IRLnA6maNuiN3em2MiRY04VgG2OJd-Sh6o2t667WgRgdTNX4re49xFQhbPzgGZy2aSNpg9WtXZNyT3Y2mK7VjfVdJLbd6MbXvevOmrbyzbPkidN1tM8P71ny7cP7r8Wn9Hr1cVlcXaeGz7hKnRWCWkoFo0bkdG1mmsuS5dy4NZ-VFjLrGBcKFLhSujVlGSulgpJKzpicZWfJq3HuLvifnY0tbqs4rDMGw1wqxqWAXng7Ck3wMQbrcBeqrQ57pIADIMQBEA63xuHW-AcQ5golDoAQe0D4AAgzBCxWyHDRj35xyNCVW7s-Dj4Q6fsvD30dja5d0I2p4lHGZlSBEL3s-yi7r2q7_yve_9P9K9xYyH4Dr7675g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78924850</pqid></control><display><type>article</type><title>Risk factors for intrahepatic recurrence of hepatocellular carcinoma in cirrhotic patients treated by percutaneous ethanol injection</title><source>Wiley Free Content</source><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Pompili, Maurizio ; Rapaccini, Gian Ludovico ; de Luca, Francescantonio ; Caturelli, Eugenio ; Astone, Antonio ; Siena, Domenico Angelo ; Villani, Maria Rosaria ; Grattagliano, Anna ; Cedrone, Augusto ; Gasbarrini, Giovanni</creator><creatorcontrib>Pompili, Maurizio ; Rapaccini, Gian Ludovico ; de Luca, Francescantonio ; Caturelli, Eugenio ; Astone, Antonio ; Siena, Domenico Angelo ; Villani, Maria Rosaria ; Grattagliano, Anna ; Cedrone, Augusto ; Gasbarrini, Giovanni</creatorcontrib><description>BACKGROUND
Hepatocellular carcinoma (HCC) complicating cirrhosis has a high intrahepatic recurrence rate after treatment by surgical resection or percutaneous ethanol injection (PEI). In this study, certain clinical, biochemical, and pathologic parameters were evaluated as risk factors for intrahepatic tumor recurrence in liver segments different from that of the first neoplasm in a group of 57 cirrhotic patients with single HCC < 5 cm treated by PEI.
METHODS
After PEI treatment of HCC, the patients were followed for a mean period of 33 ± 16 months. The following pretreatment parameters were evaluated as predictors of tumor recurrence: age, gender, Child‐Pugh score, hepatitis B virus surface antigen, hepatitis C virus antibodies, alanine aminotransferase, aspartate aminotransferase, alpha‐fetoprotein (AFP) level before PEI, alcohol abuse, HCC size, HCC ultrasound pattern, HCC histologic grade, HCC capsule, and time from cirrhosis diagnosis. Furthermore, the posttreatment parameters of the AFP level 1 month after PEI and recurrence of HCC in the same liver segment were also evaluated.
RESULTS
The cumulative 4‐year intrahepatic recurrence rate of HCC was 62%. The log rank test indicated that, among pretreatment parameters, time from cirrhosis diagnosis >6 years (P = 0.05) and AFP level before PEI of >25 ng/mL (P = 0.00005) were significantly linked to tumor recurrence. Cox's proportional hazards model showed that only AFP level before PEI was independently associated with recurrence (P < 0.002). With regard to posttreatment parameters, an AFP level 1 month after PEI of >13 ng/mL was shown to be significantly related to tumor recurrence by the log rank test (P < 0.0001).
CONCLUSIONS
Cirrhotic patients with single HCC treated by PEI who have slightly increased serum levels of AFP before and/or after PEI treatment are at increased risk of intrahepatic tumor recurrence and should undergo a close follow‐up program. Cancer 1997; 79:1501‐8. © 1997 American Cancer Society.
Cirrhotic patients with a single hepatocellular carcinoma <5 cm treated by percutaneous ethanol injection showed a high cumulative 4‐year intrahepatic recurrence of the tumor (62%). The risk of tumor recurrence in liver segments that are different from that of the first neoplasm was significantly increased in patients with serum levels of alpha‐fetoprotein > 25 ng/mL and 13 ng/mL prior to and 1 month after the treatment, respectively.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/(SICI)1097-0142(19970415)79:8<1501::AID-CNCR9>3.0.CO;2-D</identifier><identifier>PMID: 9118030</identifier><identifier>CODEN: CANCAR</identifier><language>eng</language><publisher>New York: John Wiley & Sons, Inc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Biomarkers, Tumor - blood ; Carcinoma, Hepatocellular - blood ; Carcinoma, Hepatocellular - pathology ; Carcinoma, Hepatocellular - therapy ; cirrhosis ; Ethanol - therapeutic use ; Female ; Follow-Up Studies ; Gastroenterology. Liver. Pancreas. Abdomen ; hepatocellular carcinoma ; Humans ; Italy - epidemiology ; Liver ; Liver Cirrhosis - complications ; Liver Neoplasms - blood ; Liver Neoplasms - pathology ; Liver Neoplasms - therapy ; Liver. Biliary tract. Portal circulation. Exocrine pancreas ; long term survival ; Male ; Medical sciences ; Middle Aged ; Neoplasm Recurrence, Local - blood ; Neoplasm Recurrence, Local - epidemiology ; Neoplasm Recurrence, Local - pathology ; Neoplasms, Second Primary - blood ; Neoplasms, Second Primary - epidemiology ; Neoplasms, Second Primary - pathology ; percutaneous ethanol injection ; Proportional Hazards Models ; recurrence rate ; Risk Factors ; Tumors</subject><ispartof>Cancer, 1997-04, Vol.79 (8), p.1501-1508</ispartof><rights>Copyright © 1997 American Cancer Society</rights><rights>1997 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c4649-fe551e11521c571dc6a48b274cfd46be03ef2459090fb8fd1232b890b18422863</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2F%28SICI%291097-0142%2819970415%2979%3A8%3C1501%3A%3AAID-CNCR9%3E3.0.CO%3B2-D$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2F%28SICI%291097-0142%2819970415%2979%3A8%3C1501%3A%3AAID-CNCR9%3E3.0.CO%3B2-D$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2619055$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9118030$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pompili, Maurizio</creatorcontrib><creatorcontrib>Rapaccini, Gian Ludovico</creatorcontrib><creatorcontrib>de Luca, Francescantonio</creatorcontrib><creatorcontrib>Caturelli, Eugenio</creatorcontrib><creatorcontrib>Astone, Antonio</creatorcontrib><creatorcontrib>Siena, Domenico Angelo</creatorcontrib><creatorcontrib>Villani, Maria Rosaria</creatorcontrib><creatorcontrib>Grattagliano, Anna</creatorcontrib><creatorcontrib>Cedrone, Augusto</creatorcontrib><creatorcontrib>Gasbarrini, Giovanni</creatorcontrib><title>Risk factors for intrahepatic recurrence of hepatocellular carcinoma in cirrhotic patients treated by percutaneous ethanol injection</title><title>Cancer</title><addtitle>Cancer</addtitle><description>BACKGROUND
Hepatocellular carcinoma (HCC) complicating cirrhosis has a high intrahepatic recurrence rate after treatment by surgical resection or percutaneous ethanol injection (PEI). In this study, certain clinical, biochemical, and pathologic parameters were evaluated as risk factors for intrahepatic tumor recurrence in liver segments different from that of the first neoplasm in a group of 57 cirrhotic patients with single HCC < 5 cm treated by PEI.
METHODS
After PEI treatment of HCC, the patients were followed for a mean period of 33 ± 16 months. The following pretreatment parameters were evaluated as predictors of tumor recurrence: age, gender, Child‐Pugh score, hepatitis B virus surface antigen, hepatitis C virus antibodies, alanine aminotransferase, aspartate aminotransferase, alpha‐fetoprotein (AFP) level before PEI, alcohol abuse, HCC size, HCC ultrasound pattern, HCC histologic grade, HCC capsule, and time from cirrhosis diagnosis. Furthermore, the posttreatment parameters of the AFP level 1 month after PEI and recurrence of HCC in the same liver segment were also evaluated.
RESULTS
The cumulative 4‐year intrahepatic recurrence rate of HCC was 62%. The log rank test indicated that, among pretreatment parameters, time from cirrhosis diagnosis >6 years (P = 0.05) and AFP level before PEI of >25 ng/mL (P = 0.00005) were significantly linked to tumor recurrence. Cox's proportional hazards model showed that only AFP level before PEI was independently associated with recurrence (P < 0.002). With regard to posttreatment parameters, an AFP level 1 month after PEI of >13 ng/mL was shown to be significantly related to tumor recurrence by the log rank test (P < 0.0001).
CONCLUSIONS
Cirrhotic patients with single HCC treated by PEI who have slightly increased serum levels of AFP before and/or after PEI treatment are at increased risk of intrahepatic tumor recurrence and should undergo a close follow‐up program. Cancer 1997; 79:1501‐8. © 1997 American Cancer Society.
Cirrhotic patients with a single hepatocellular carcinoma <5 cm treated by percutaneous ethanol injection showed a high cumulative 4‐year intrahepatic recurrence of the tumor (62%). The risk of tumor recurrence in liver segments that are different from that of the first neoplasm was significantly increased in patients with serum levels of alpha‐fetoprotein > 25 ng/mL and 13 ng/mL prior to and 1 month after the treatment, respectively.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - blood</subject><subject>Carcinoma, Hepatocellular - blood</subject><subject>Carcinoma, Hepatocellular - pathology</subject><subject>Carcinoma, Hepatocellular - therapy</subject><subject>cirrhosis</subject><subject>Ethanol - therapeutic use</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>hepatocellular carcinoma</subject><subject>Humans</subject><subject>Italy - epidemiology</subject><subject>Liver</subject><subject>Liver Cirrhosis - complications</subject><subject>Liver Neoplasms - blood</subject><subject>Liver Neoplasms - pathology</subject><subject>Liver Neoplasms - therapy</subject><subject>Liver. Biliary tract. Portal circulation. Exocrine pancreas</subject><subject>long term survival</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local - blood</subject><subject>Neoplasm Recurrence, Local - epidemiology</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Neoplasms, Second Primary - blood</subject><subject>Neoplasms, Second Primary - epidemiology</subject><subject>Neoplasms, Second Primary - pathology</subject><subject>percutaneous ethanol injection</subject><subject>Proportional Hazards Models</subject><subject>recurrence rate</subject><subject>Risk Factors</subject><subject>Tumors</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU-P0zAQxSMEWroLHwHJB4R2Dyljx27sLkKsUv5UWlFpAWk5jRzXVrOkcbETrXrng5NsSi8gcbI8897ozfyS5B2FKQVgr8-_LIvlBQWVp0A5O6dK5cCpuMjVXL6hAuh8frVcpMXn4ka9zaYwLVaXLF08SiZH0-NkAgAyFTy7fZqcxnjXf3MmspPkRFEqIYNJ8uumij-I06b1IRLnA6maNuiN3em2MiRY04VgG2OJd-Sh6o2t667WgRgdTNX4re49xFQhbPzgGZy2aSNpg9WtXZNyT3Y2mK7VjfVdJLbd6MbXvevOmrbyzbPkidN1tM8P71ny7cP7r8Wn9Hr1cVlcXaeGz7hKnRWCWkoFo0bkdG1mmsuS5dy4NZ-VFjLrGBcKFLhSujVlGSulgpJKzpicZWfJq3HuLvifnY0tbqs4rDMGw1wqxqWAXng7Ck3wMQbrcBeqrQ57pIADIMQBEA63xuHW-AcQ5golDoAQe0D4AAgzBCxWyHDRj35xyNCVW7s-Dj4Q6fsvD30dja5d0I2p4lHGZlSBEL3s-yi7r2q7_yve_9P9K9xYyH4Dr7675g</recordid><startdate>19970415</startdate><enddate>19970415</enddate><creator>Pompili, Maurizio</creator><creator>Rapaccini, Gian Ludovico</creator><creator>de Luca, Francescantonio</creator><creator>Caturelli, Eugenio</creator><creator>Astone, Antonio</creator><creator>Siena, Domenico Angelo</creator><creator>Villani, Maria Rosaria</creator><creator>Grattagliano, Anna</creator><creator>Cedrone, Augusto</creator><creator>Gasbarrini, Giovanni</creator><general>John Wiley & Sons, Inc</general><general>Wiley-Liss</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19970415</creationdate><title>Risk factors for intrahepatic recurrence of hepatocellular carcinoma in cirrhotic patients treated by percutaneous ethanol injection</title><author>Pompili, Maurizio ; Rapaccini, Gian Ludovico ; de Luca, Francescantonio ; Caturelli, Eugenio ; Astone, Antonio ; Siena, Domenico Angelo ; Villani, Maria Rosaria ; Grattagliano, Anna ; Cedrone, Augusto ; Gasbarrini, Giovanni</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4649-fe551e11521c571dc6a48b274cfd46be03ef2459090fb8fd1232b890b18422863</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - blood</topic><topic>Carcinoma, Hepatocellular - blood</topic><topic>Carcinoma, Hepatocellular - pathology</topic><topic>Carcinoma, Hepatocellular - therapy</topic><topic>cirrhosis</topic><topic>Ethanol - therapeutic use</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>hepatocellular carcinoma</topic><topic>Humans</topic><topic>Italy - epidemiology</topic><topic>Liver</topic><topic>Liver Cirrhosis - complications</topic><topic>Liver Neoplasms - blood</topic><topic>Liver Neoplasms - pathology</topic><topic>Liver Neoplasms - therapy</topic><topic>Liver. Biliary tract. Portal circulation. Exocrine pancreas</topic><topic>long term survival</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local - blood</topic><topic>Neoplasm Recurrence, Local - epidemiology</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Neoplasms, Second Primary - blood</topic><topic>Neoplasms, Second Primary - epidemiology</topic><topic>Neoplasms, Second Primary - pathology</topic><topic>percutaneous ethanol injection</topic><topic>Proportional Hazards Models</topic><topic>recurrence rate</topic><topic>Risk Factors</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pompili, Maurizio</creatorcontrib><creatorcontrib>Rapaccini, Gian Ludovico</creatorcontrib><creatorcontrib>de Luca, Francescantonio</creatorcontrib><creatorcontrib>Caturelli, Eugenio</creatorcontrib><creatorcontrib>Astone, Antonio</creatorcontrib><creatorcontrib>Siena, Domenico Angelo</creatorcontrib><creatorcontrib>Villani, Maria Rosaria</creatorcontrib><creatorcontrib>Grattagliano, Anna</creatorcontrib><creatorcontrib>Cedrone, Augusto</creatorcontrib><creatorcontrib>Gasbarrini, Giovanni</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pompili, Maurizio</au><au>Rapaccini, Gian Ludovico</au><au>de Luca, Francescantonio</au><au>Caturelli, Eugenio</au><au>Astone, Antonio</au><au>Siena, Domenico Angelo</au><au>Villani, Maria Rosaria</au><au>Grattagliano, Anna</au><au>Cedrone, Augusto</au><au>Gasbarrini, Giovanni</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Risk factors for intrahepatic recurrence of hepatocellular carcinoma in cirrhotic patients treated by percutaneous ethanol injection</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>1997-04-15</date><risdate>1997</risdate><volume>79</volume><issue>8</issue><spage>1501</spage><epage>1508</epage><pages>1501-1508</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><coden>CANCAR</coden><abstract>BACKGROUND
Hepatocellular carcinoma (HCC) complicating cirrhosis has a high intrahepatic recurrence rate after treatment by surgical resection or percutaneous ethanol injection (PEI). In this study, certain clinical, biochemical, and pathologic parameters were evaluated as risk factors for intrahepatic tumor recurrence in liver segments different from that of the first neoplasm in a group of 57 cirrhotic patients with single HCC < 5 cm treated by PEI.
METHODS
After PEI treatment of HCC, the patients were followed for a mean period of 33 ± 16 months. The following pretreatment parameters were evaluated as predictors of tumor recurrence: age, gender, Child‐Pugh score, hepatitis B virus surface antigen, hepatitis C virus antibodies, alanine aminotransferase, aspartate aminotransferase, alpha‐fetoprotein (AFP) level before PEI, alcohol abuse, HCC size, HCC ultrasound pattern, HCC histologic grade, HCC capsule, and time from cirrhosis diagnosis. Furthermore, the posttreatment parameters of the AFP level 1 month after PEI and recurrence of HCC in the same liver segment were also evaluated.
RESULTS
The cumulative 4‐year intrahepatic recurrence rate of HCC was 62%. The log rank test indicated that, among pretreatment parameters, time from cirrhosis diagnosis >6 years (P = 0.05) and AFP level before PEI of >25 ng/mL (P = 0.00005) were significantly linked to tumor recurrence. Cox's proportional hazards model showed that only AFP level before PEI was independently associated with recurrence (P < 0.002). With regard to posttreatment parameters, an AFP level 1 month after PEI of >13 ng/mL was shown to be significantly related to tumor recurrence by the log rank test (P < 0.0001).
CONCLUSIONS
Cirrhotic patients with single HCC treated by PEI who have slightly increased serum levels of AFP before and/or after PEI treatment are at increased risk of intrahepatic tumor recurrence and should undergo a close follow‐up program. Cancer 1997; 79:1501‐8. © 1997 American Cancer Society.
Cirrhotic patients with a single hepatocellular carcinoma <5 cm treated by percutaneous ethanol injection showed a high cumulative 4‐year intrahepatic recurrence of the tumor (62%). The risk of tumor recurrence in liver segments that are different from that of the first neoplasm was significantly increased in patients with serum levels of alpha‐fetoprotein > 25 ng/mL and 13 ng/mL prior to and 1 month after the treatment, respectively.</abstract><cop>New York</cop><pub>John Wiley & Sons, Inc</pub><pmid>9118030</pmid><doi>10.1002/(SICI)1097-0142(19970415)79:8<1501::AID-CNCR9>3.0.CO;2-D</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0008-543X |
| ispartof | Cancer, 1997-04, Vol.79 (8), p.1501-1508 |
| issn | 0008-543X 1097-0142 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_78924850 |
| source | Wiley Free Content; MEDLINE; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Adult Aged Aged, 80 and over Antineoplastic Agents - therapeutic use Biological and medical sciences Biomarkers, Tumor - blood Carcinoma, Hepatocellular - blood Carcinoma, Hepatocellular - pathology Carcinoma, Hepatocellular - therapy cirrhosis Ethanol - therapeutic use Female Follow-Up Studies Gastroenterology. Liver. Pancreas. Abdomen hepatocellular carcinoma Humans Italy - epidemiology Liver Liver Cirrhosis - complications Liver Neoplasms - blood Liver Neoplasms - pathology Liver Neoplasms - therapy Liver. Biliary tract. Portal circulation. Exocrine pancreas long term survival Male Medical sciences Middle Aged Neoplasm Recurrence, Local - blood Neoplasm Recurrence, Local - epidemiology Neoplasm Recurrence, Local - pathology Neoplasms, Second Primary - blood Neoplasms, Second Primary - epidemiology Neoplasms, Second Primary - pathology percutaneous ethanol injection Proportional Hazards Models recurrence rate Risk Factors Tumors |
| title | Risk factors for intrahepatic recurrence of hepatocellular carcinoma in cirrhotic patients treated by percutaneous ethanol injection |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T01%3A54%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Risk%20factors%20for%20intrahepatic%20recurrence%20of%20hepatocellular%20carcinoma%20in%20cirrhotic%20patients%20treated%20by%20percutaneous%20ethanol%20injection&rft.jtitle=Cancer&rft.au=Pompili,%20Maurizio&rft.date=1997-04-15&rft.volume=79&rft.issue=8&rft.spage=1501&rft.epage=1508&rft.pages=1501-1508&rft.issn=0008-543X&rft.eissn=1097-0142&rft.coden=CANCAR&rft_id=info:doi/10.1002/(SICI)1097-0142(19970415)79:8%3C1501::AID-CNCR9%3E3.0.CO;2-D&rft_dat=%3Cproquest_cross%3E78924850%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=78924850&rft_id=info:pmid/9118030&rfr_iscdi=true |